Newamsterdam Pharma B.V.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Dezima Pharma B.V. (to 2022)
2
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors (US 10,300,059) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,872,126 | Tetrahydroquinoline derivatives and a process for preparing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 8,084,611 | Process for preparing tetrahydroquinoline derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 10,653,692 | Cholesteryl Ester Transfer Protein (CETP) Inhibitor and Pharmaceutical Compositions Comprising Said Inhibitor for Use in the Treatment or Prevention of Cardiovascular Diseases In force · High confidence | In force | High confidence | |
| US 11,013,742 | Cholesteryl Ester Transfer Protein (CETP) Inhibitor and Pharmaceutical Compositions Comprising Said Inhibitor for Use in the Treatment or Prevention of Cardiovascular Diseases In force · Medium confidence | In force | Medium confidence | |
| US 12,186,315 | Cholesteryl Ester Transfer Protein (CETP) Inhibitor and Pharmaceutical Compositions Comprising Said Inhibitor for Use in the Treatment or Prevention of Cardiovascular Diseases In force · Medium confidence | In force | Medium confidence | |
| US 12,734,171 | Cholesteryl Ester Transfer Protein (CETP) Inhibitor and Pharmaceutical Compositions Comprising Said Inhibitor for Use in the Treatment or Prevention of Cardiovascular Diseases In force · Medium confidence | In force | Medium confidence | |
| US 10,112,904 | Process for Preparing Synthetic Intermediates for Preparing Tetrahydroquinoline Derivatives In force · High confidence | In force | High confidence | |
| US 10,300,059 | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 12,006,305 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof In force · High confidence | In force | High confidence | |
| US 12,378,221 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 1 patent in force now held by others · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned